Articles dans des revues avec comité de lecture (396)
  1. 145. Thomas, F., Desmedt, C., Aftimos, P., & Awada, A. (2014). Impact of tumor sequencing on the use of anticancer drugs. Current opinion in oncology, 26(3), 347-356. doi:10.1097/CCO.0000000000000078
  2. 146. Awada, A., & Aftimos, P. (2014). Foreword for the edition of Treatment Strategies. Oncology, 4(1), 9.
  3. 147. Polastro, L., Aftimos, P., & Awada, A. (2014). Eribulin Mesylate in the management of metastatic breast cancer and other solid cancers: A drug review. Expert review of anticancer therapy, 14(6), 649-665. doi:10.1586/14737140.2014.920693
  4. 148. Raymond, É. E., Faivre, S., Alexandre, J., Goldwasser, F., Besse-Hammer, T., Awada, A., Gianella-Borradori, A., Jego, V., Trandafir, L., & Rejeb, N. (2014). A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors. Investigational new drugs, 32(1), 94-103. doi:10.1007/s10637-013-9950-y
  5. 149. Ades Moraes, F., Zardavas, D., Aftimos, P., & Awada, A. (2014). Anticancer drug development: Moving away from the old habits. Current opinion in oncology, 26(3), 334-339. doi:10.1097/CCO.0000000000000076
  6. 150. Bartsch, R., Berghoff, A. S., Zielinski, C., Gnant, M., Frings, S., Marty, M., Awada, A., Conte, P., Dickin, S., Enzmann, H., Hasmann, M., Hendriks, H. H., Llombart, A., Massacesi, C., Von Minckwitz, G., Pénault-Llorca, F., Scaltriti., M., Yarden, Y., & Zwierzina, H. (2014). Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry. Annals of oncology, 25(4), mdt531, 773-780. doi:10.1093/annonc/mdt531
  7. 151. Awada, A., Piccart-Gebhart, M., Bondarenko, I. I., Bonneterre, J., Nowara, E., Ferrero, J. M., Bakshi, A. V., & Wilke, C. M. C. (2014). A randomized controlled phase ii trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (tnbc). Annals of oncology, 25(4), mdu025, 824-831. doi:10.1093/annonc/mdu025
  8. 152. Awada, A., Nicaise, C., Ena, S., Schandené, L., Rasschaert, J., Ristea-Popescu, A. I., Gangji, V., & Soyfoo, M. S. (2014). Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 73, 1259-1263. doi:10.1136/annrheumdis-2012-203187
  9. 153. Martin, M., Bonneterre, J., Geyer Jr., C. C., Ito, Y., Ro, J., Lang, I., Kim, S.-B., Germa, C., Vermette, J., Wang, K., Wang, K., & Awada, A. (2013). A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. European journal of cancer, 49(18), 3763-3772. doi:10.1016/j.ejca.2013.07.142
  10. 154. de Azambuja, E., Zardavas, D., Lemort, M., Rossari, J., Moulin, C., Buttice, A., D'Hondt, V., Lebrun, F., Lalami, Y., Cardoso, F., Sotiriou, C., Gil, T., Devriendt, D., Paesmans, M., Piccart-Gebhart, M., & Awada, A. (2013). Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial. Annals of oncology, 24(12), 2985-2989. doi:10.1093/annonc/mdt359
  11. 155. Awada, A., Garcia, A. A., Chan, S., Jerusalem, G., Coleman, R., Huizing, M. T., Mehdi, A., O'Reilly, S. M., Hamm, J. T., Barrett-Lee, P., Cocquyt, V., Sideras, K., Young, D. E., Zhao, C., Chia, Y. L., Hoch, U., Hannah, A. L., & Perez, E. A. (2013). Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: A randomised phase 2 study. Lancet oncology, 14(12), 1216-1225. doi:10.1016/S1470-2045(13)70429-7
  12. 156. Zakkouri, F. F., Errihani, H., Klastersky, J., Georgala, A., Alexiou, J., De Saint Aubain, N., Flamen, P., Firescu, R., & Awada, A. (2013). Histiocytose agressive à cellules de Langerhans 20 ans après un cancer du sein: À propos d'un cas. Journal africain du cancer, 5(4), 220-223. doi:10.1007/s12558-013-0276-7
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>